中國(guó)將17種抗癌藥物列入醫(yī)療保險(xiǎn)清單

China has included 17 cancer drugs on the medical insurance list, the country’s state medical insurance administration announced on Wednesday.

中國(guó)國(guó)家醫(yī)療保險(xiǎn)總局周三宣布，中國(guó)已將17種抗癌藥物列入醫(yī)療保險(xiǎn)名單。

The price of the 17 drugs dropped 56.7 percent averagely compared to the average retail price. And, they have been priced lower than the market prices in the neighboring countries and regions, remarkably reducing the economic burden of people battling cancer in China.

與平均零售價(jià)相比，這17種藥品的價(jià)格平均下跌了56.7%。而且，它們的價(jià)格已經(jīng)低于在中國(guó)鄰國(guó)地區(qū)的市場(chǎng)價(jià)格，這大大減輕了中國(guó)癌癥患者的經(jīng)濟(jì)負(fù)擔(dān)。

This June, China’s drug authority launched a new round of negotiations with pharmaceutical companies on the inclusion of cancer drugs for medical insurance.

今年6月，中國(guó)藥監(jiān)局啟動(dòng)了新一輪與制藥公司的談判，內(nèi)容是將抗癌藥物納入醫(yī)療保險(xiǎn)。

44 cancer drugs that were not covered in the list were reviewed during the negotiations, and 17 drugs were finally selected to be added on the list.

在談判中再次審議了此前44種未列入清單的癌癥藥物，最后選定17種藥物列入清單。

All of them are clinically necessary, effective, and urgently needed for cancer treatment.

它們都是臨床上治療癌癥所必需的、有效的和迫切需要的藥物。

The move also reflects the country’s support for medical innovation and stronger push for research and development. 10 of the 17 newly included drugs have been publicly available since last year.

此舉也反映出中國(guó)對(duì)醫(yī)療創(chuàng)新的支持，以及對(duì)醫(yī)療研發(fā)的更大推動(dòng)。自去年以來(lái)，新納入的17種藥物中有10種已經(jīng)公開(kāi)上市。